Home » Topics » Disease categories and therapies » Dermatologic

Dermatologic
RSS

Taro's clobetasol propionate approved by FDA

July 19, 1996

Stiefel to develop and market CytoMed's CMI-392

July 19, 1996

OncorPharm acquires rights to dithymidine-based products

July 12, 1996

ProCyte seeks FDA marketing clearance for OsmoCyte

July 12, 1996

FDA issues nonapprovable letter for Avita; development elsewhere on track

July 5, 1996

ProCyte launches Iamin gel in U.S.

July 5, 1996

ICN's Viquin Forte launched in U.S.

June 28, 1996

Connective Therapeutics to develop new formulation of betamethasone valerate

June 28, 1996

Collagen Corporation and Biomatrix enter marketing agreement

June 21, 1996

KCB-1 skin ulcer clinical trials completed

June 21, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...